Lantheus (LNTH)
(Delayed Data from NSDQ)
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Boston Scientific Grows on Innovation, Buyouts Amid Woes
by Zacks Equity Research
While unfavorable foreign exchange continues to raise concerns, Boston Scientific (BSX) stands steadily on growth track with Symetis acquisition and FDA-approved products.
Myriad Genetics Boosts myRisk Hereditary Cancer Test Suite
by Zacks Equity Research
Myriad Genetics (MYGN) introduces riskScore, a breast cancer prediction tool to broaden its myRisk hereditary cancer test offerings.
HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered favorable results in the second quarter of fiscal 2018 on the back of revenue and margin expansion.
Allscripts' (MDRX) dbMotion Platform Selected by SWSPHN
by Zacks Equity Research
The latest development is a significant addition to Allscripts' (MDRX) dbMotion Solution platform customer base. The company is poised to benefit from opportunities in the Asia-Pacific market.
Henry Schein Joins IMF & LUGFA on Prostate Cancer Awareness
by Zacks Equity Research
Henry Schein (HSIC) joins forces with IMF and LUGPA to generate awareness among physicians and people about the importance of early detection of prostate cancer.
Quest Diagnostics (DGX) Banks on Buyouts, Competition Rife
by Zacks Equity Research
Quest Diagnostics (DGX) witnesses significant growth through infectious disease testing, prescription drug monitoring and wellness business.
Medtronic (MDT) & Mazor Robotics Tie-Up Reaches Next Level
by Zacks Equity Research
With an investment of $40 million as a third installment in Mazor Robotics, Medtronic (MDT) will become the exclusive worldwide distributor of the Mazor X system.
Ride Out MedTech Volatility With These 3 Ultra-Safe Stocks
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these three low-beta MedTech stocks stand out as the most suitable value picks.
Hologic (HOLX) Launches Brevera, Progresses in Breast Health
by Zacks Equity Research
Hologic's (HOLX) Brevera real-time breast biopsy and verification system holds great potential to enhance workflow and patient experience.
Mazor Robotics Hits 52-Week High Through Medtronic Alliance
by Zacks Equity Research
Mazor Robotics (MZOR) touched a new 52-week high on the back of favorable amendment of its strategic partnership with Medtronic.
GNC Holdings Gains on New GNC Strength Amid Soft Revenues
by Zacks Equity Research
GNC Holdings (GNC) continues to bank on new GNC plan and global revenues despite lacklustre revenue figures in second quarter of 2017.
Haemonetics Grows on Strong Plasma, Blood Center Sluggish
by Zacks Equity Research
Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.
Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod
by Zacks Equity Research
Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest Japanese national reimbursement grant.
Amedisys to Buy Intercity Home Care, Boosts Personal Care Arm
by Zacks Equity Research
Amedisys (AMED) to strengthen its position in Personal Care business in Massachusetts with this recently signed acquisition deal.
Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm
by Zacks Equity Research
Abbott (ABT) is consistently trying to expand its vascular business. It has initiated the clinical study of AMPLATZER device to correct common congenital heart defect in newborns.
BioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised)
by Zacks Equity Research
BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.
3 Excellent Value Picks as Political Chaos Grips MedTech
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these three MedTech stocks stand out as the most suitable value picks.
Zacks.com featured highlights include Lantheus Holdings, Jazz Pharmaceuticals, Gray Television, Aetna and Uniti Group
by Zacks Equity Research
Zacks.com featured highlights include Lantheus Holdings, Jazz Pharmaceuticals, Gray Television, Aetna and Uniti Group
VWR Awaits Merger Closure, Stock Upside Potential Limited
by Zacks Equity Research
VWR Corporation's (VWR) $6.4 billion acquisition by Avantor should create a major consumables-focused solutions and services provider to lucrative life sciences and advanced technologies industries.
Cooper (COO) Poised to Grow on Specialty Lenses Prospects
by Zacks Equity Research
Cooper's (COO) strong sales growth will continue to be aided by its leading position in the markets of specialty lenses.
Accuray (ARAY) Grapples With Falling Margin and Product Mix
by Zacks Equity Research
Accuray Inc.'s (ARAY) low product margins and unfavorable product mix will continue to be a drag on the company's performance.
Thermo Fisher Acquires Patheon, Boosts Laboratory Products
by Zacks Equity Research
Thermo Fisher's (TMO) acquisition of Patheon significantly strengthens its Pharmaceutical and Biotech business by adding complementary services.
Here's Why You Should Buy Lantheus Holdings (LNTH) Right Now
by Zacks Equity Research
Lantheus Holdings (LNTH) banks on DEFINITY and TechneLite sales for growth. The company's focus on global expansion is also encouraging.
5 Excellent Value Stocks Based on Low PEG Ratio
by Zacks Equity Research
While P/E alone fails to identify a true value stock, PEG helps find the intrinsic value of a stock.
Intuitive Surgical (ISRG) Well Poised on Procedural Business
by Zacks Equity Research
Intuitive Surgical's (ISRG) strong sales growth will continue to be aided by focus on da Vinci system and procedural growth from general surgery, oncology, urology and gynecology.